At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 250 target
Drug / intervention
inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentre Perspective Non-interventional Study of Survival Benefits of iCAGES-guided Therapy in Contrast to Standard Therapy or IHC-guided Therapy for Advanced Cancers
Second Affiliated Hospital of Guangzhou Medical University·observational·Posted Jun 20, 2017·Updated Jun 25, 2024
In Brief
An observational study evaluating inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group. for Lung Cancer and 3 related conditions. Currently recruiting, targeting 250 participants across 1 site.
Detailed Summary
This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Gene Abnormality, Gene Product Sequence Variation, Cancer
CountriesChina
Timeline
N/ARecruiting
201720182019202020212022202320242025202620272028202920302031203220332034203520362037203820392040
First PostedJun 2017
Enrollment StartJul 2017
TodayJul 2026
Primary CompletionJul 2030
Study CompletionJul 2039
First PostedJun 20, 2017
Enrollment StartJul 1, 2017
Primary CompletionJul 1, 2030
Study CompletionJul 1, 2039
TodayJul 1, 2026
Enrollment to primary: 13 yearsPosted 9.0 years agoPrimary completion in 4 years
Interventions
inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.drug
Choose appropriate targeted drugs according to NGS/IHC results.